S-nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface |
| |
Authors: | Khalequz Zaman Deric Bennett Maya Fraser-Butler Zivi Greenberg Paulina Getsy Abdus Sattar Laura Smith Deborah Corey Fei Sun John Hunt Stephen J Lewis Benjamin Gaston |
| |
Institution: | 1. Pediatric Pulmonology Division, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA;2. Pediatric Respiratory Medicine, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA;3. Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA;4. Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201, USA |
| |
Abstract: | S-nitrosothiols (SNOs) are endogenous signaling molecules with a broad spectrum of beneficial airway effects. SNOs are normally present in the airway, but levels tend to be low in cystic fibrosis (CF) patients. We and others have demonstrated that S-nitrosoglutathione (GSNO) increases the expression, maturation, and function of wild-type and mutant F508del cystic fibrosis transmembrane conductance regulator (CFTR) in human bronchial airway epithelial (HBAE) cells. We hypothesized that membrane permeable SNOs, such as S-nitrosoglutathione diethyl ester (GNODE) and S-nitroso-N-acetyl cysteine (SNOAC) may be more efficient in increasing the maturation of CFTR. HBAE cells expressing F508del CFTR were exposed to GNODE and SNOAC. The effects of these SNOs on the expression and maturation of F508del CFTR were determined by cell surface biotinylation and Western blot analysis. We also found for the first time that GNODE and SNOAC were effective at increasing CFTR maturation at the cell surface. Furthermore, we found that cells maintained at low temperature increased cell surface stability of F508del CFTR whereas the combination of low temperature and SNO treatment significantly extended the half-life of CFTR. Finally, we showed that SNO decreased the internalization rate of F508del CFTR in HBAE cells. We anticipate identifying the novel mechanisms, optimal SNOs, and lowest effective doses which could benefit cystic fibrosis patients. |
| |
Keywords: | Cystic fibrosis CFTR S-nitrosothiol S-nitrosylation Chaperones Molecular therapy |
本文献已被 ScienceDirect 等数据库收录! |
|